Tenaya Therapeutics, Inc. TNYA
We are a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease.
Heart disease remains the leading cause of death in the world. In the U.S., one person dies from a cardiovascular-related health condition every 34 seconds, a gruesome statistic that translates to one in every three deaths in the U.S each year. One in 20 adults suffer from congenital heart disease (CHD) and the picture is equally bleak at the other end of the age spectrum, as approximately 40,000 children are born in the U.S every year with CHD, the leading cause of birth defect-related morbidity and mortality. While there is a clear need for improved treatments, the rate of cardiovascular drug product approvals has declined in recent years and few of the approved treatments address the underlying cause of such diseases.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D | $68.6M | $86.7M | $98.0M | $94.5M | $54.4M | $31.1M | — |
| SG&A | $24.7M | $29.2M | $33.2M | $31.1M | $18.4M | $7.8M | — |
| Total operating expenses | $93.3M | $115.9M | $131.2M | $125.6M | $72.8M | $38.9M | — |
| Operating income | -$93.3M | -$115.9M | -$131.2M | -$125.6M | -$72.8M | -$38.9M | — |
| Pre-tax income | -$90.6M | -$111.1M | -$124.1M | -$123.7M | -$72.7M | -$38.4M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$90.6M | -$111.1M | -$124.1M | -$123.7M | -$72.7M | -$38.4M | — |
| EPS, basic | -0.59 | -1.31 | -1.68 | -2.76 | -4.10 | — | — |
| EPS, diluted | -0.59 | -1.31 | -1.68 | -2.76 | -4.10 | -39.50 | — |
| Shares, diluted (wtd. avg.) | 153.0M | 84.8M | 73.8M | 44.8M | 17.7M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $100.5M | $4.3M | $45.7M | $95.3M | $38.1M | $128.5M | — |
| Short-term investments | — | $57.1M | $59.0M | $91.3M | $213.2M | — | — |
| Total current assets | $105.6M | $67.4M | $111.6M | $193.8M | $255.4M | $130.0M | — |
| Property, plant and equipment | $27.7M | $35.9M | $43.3M | $51.0M | $43.0M | $17.2M | — |
| Total assets | $146.9M | $119.9M | $170.5M | $278.9M | $314.2M | $148.2M | — |
| Accounts payable | $3.6M | $5.2M | $5.6M | $9.6M | $10.7M | $1.0M | — |
| Total current liabilities | $15.4M | $16.0M | $22.7M | $24.2M | $21.8M | $5.0M | — |
| Total liabilities | $23.7M | $27.1M | $31.1M | $35.6M | $35.7M | $8.7M | — |
| Retained earnings | -$605.0M | -$514.4M | -$403.3M | -$279.2M | -$155.5M | -$82.8M | — |
| Total equity | $123.3M | $92.9M | $139.4M | $243.4M | $278.5M | -$81.3M | -$43.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$68.3M | -$90.5M | -$102.1M | -$104.4M | -$60.8M | -$35.4M | — |
| Depreciation and amortisation | $8.4M | $8.5M | $8.7M | $6.5M | $3.0M | $2.5M | — |
| Stock-based compensation | $13.0M | $16.5M | $15.3M | $11.5M | $3.0M | $741.0K | — |
| Capital expenditure | $618.0K | $1.0M | $1.2M | $20.6M | $25.1M | $9.8M | — |
| Investing cash flow | $56.1M | $1.1M | $48.7M | $83.7M | -$238.6M | -$7.0M | — |
| Financing cash flow | $108.4M | $47.7M | $4.0M | $77.8M | $209.0M | $147.3M | — |
| Buybacks | — | — | — | — | $13.0K | $1.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-102252.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$38.4M | -$72.7M | -$123.7M | -$124.1M | -$111.1M | -$90.6M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |